A carregar...
Combination therapy with androgen receptor N‐terminal domain antagonist EPI‐7170 and enzalutamide yields synergistic activity in AR‐V7‐positive prostate cancer
Resistance of castration‐resistant prostate cancer (CRPC) to enzalutamide and abiraterone involves the expression of constitutively active, truncated androgen receptor (AR) splice variants (AR‐Vs) that lack a C‐terminal ligand‐binding domain (LBD). Both full‐length AR and truncated AR‐Vs require a f...
Na minha lista:
| Publicado no: | Mol Oncol |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7530779/ https://ncbi.nlm.nih.gov/pubmed/32734688 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/1878-0261.12770 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|